Abstract:Liver X nuclear receptor (LXR) agonists are promising anti-atherosclerotic agents that increase the expression of cholesterol transporters on atheroma macrophages leading to increased efflux of cholesterol to endogenous high-density lipoprotein (HDL) acceptors. HDL subsequently delivers effluxed cholesterol to the liver by the process of reverse cholesterol transport, resulting in reduction of atherosclerotic plaques. However, LXR agonists administration triggers undesirable liver steatosis and hypertriglyceridemia due to increased fatty acid and sterol synthesis. LXR-induced liver toxicity, poor drug aqueous solubility and low levels of endogenous HDL acceptors in target patient populations limit the clinical translation of LXR agonists. Here, we propose a dual-antiatherogenic strategy for administration of the LXR agonist, T0901317 (T1317), by encapsulating in synthetic HDL (sHDL) nanoparticles. sHDL had been clinically proven to serve as cholesterol acceptors, resulting in plaque reduction in atherosclerosis patients. In addition, the hydrophobic core and endogenous atheroma-targeting ability of sHDL allow for encapsulation of water-insoluble drugs and their subsequent delivery to atheroma. Several compositions of sHDL were tested to optimize both T1317 encapsulation efficiency and ability of T1317-sHDL to efflux cholesterol. Optimized T1317-sHDL exhibited more efficient cholesterol efflux from macrophages and enhanced atheroma-targeting relative to free drug. Most importantly, in an apolipoprotein E deficient (ApoE-/-) atherosclerosis progression murine model, T1317-sHDL showed superior inhibition of atherogenesis and reduced hypertriglyceridemia side effects in comparison to the free drug and blank sHDL. The T1317-sHDL pharmacological efficacy was observed at doses lower than those previously described for LXR agents, which may have additional safety benefits. In addition, the established clinical manufacturing, safety and efficacy of blank sHDL nanoparticles used in this study could facilitate future clinical translation of LXR-loaded sHDLs.

Synthesis of liver X receptor agonists from hydeoxycholic acid

Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease

Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists

Discovery of Tissue Selective Liver X Receptor Agonists for the Treatment of Atherosclerosis Without Causing Hepatic Lipogenesis.

Diterpenoid, Steroid, And Triterpenoid Agonists Of Liver X Receptors From Diversified Terrestrial Plants And Marine Sources

New Drug Targets LXR for Cholesterol Control

Liver X receptors as potential therapeutic targets for multiple diseases.

Discovery of Anti-Hypercholesterolemia Agents Targeting LXRα from Marine Microorganism-Derived Natural Products

Discovery of novel liver X receptor inverse agonists as lipogenesis inhibitors

Identification of Side Chain Oxidized Sterols As Novel Liver X Receptor Agonists with Therapeutic Potential in the Treatment of Cardiovascular and Neurodegenerative Diseases

Synthetic High-Density Lipoproteins Delivering Liver X Receptor Agonist Prevent Atherogenesis by Enhancing Reverse Cholesterol Transport.

Liver X receptors：the new orientation of drugs for metabolic diseases

Lipid reducing activity of novel cholic acid (CA) analogs: Design, synthesis and preliminary mechanism study.

Identification of A Novel Partial Agonist of Liver X Receptor Alpha (lxr Alpha) Via Screening

Identify Liver X Receptor Β Modulator Building Blocks by Developing a Fluorescence Polarization-Based Competition Assay.

Liver X Receptors And Their Agonists: Targeting For Cholesterol Homeostasis And Cardiovascular Diseases

LXR agonists: new potential therapeutic drug for neurodegenerative diseases

Structure Optimization of 12β-O-γ-Glutamyl Oleanolic Acid Derivatives Resulting in Potent FXR Antagonist/Modulator for NASH Therapy

Synthesis and Identification of New Flavonoids Targeting Liver X Receptor Β Involved Pathway As Potential Facilitators of Aβ Clearance with Reduced Lipid Accumulation.

Liver X Receptors As Potential Therapeutic Targets in Atherosclerosis

Structurally Selective Mechanism of Liver X Receptor Ligand: in Silico and in Vitro Studies.